COVID Treatment Shows Encouraging Results in Trial, Study Says Voice of America - VOA News
See more here:
COVID Treatment Shows Encouraging Results in Trial, Study Says - Voice of America - VOA News
OverviewWhat is mpox?
Mpox is a rare disease caused by the mpox virus. It leads to rash and flu-like symptoms. Like the better-known virus that causes smallpox, its a member of the family called orthopoxvirus.
Mpox was discovered in 1958 when two outbreaks of a pox-like disease occurred in groups of monkeys being used for research. Its spread mainly through human contact with infected rodents, but can sometimes be spread through skin-to-skin contact with a person who is infected. There are two known types (clades) of mpox virus one that originated in Central Africa and one that originated in West Africa. The current world outbreak (2022) is caused by the less severe West African clade.
Mpox is rare. But the number of cases is increasing in Africa, as well as in regions that havent seen these infections before.
For decades, mpox was mostly been seen in Africa. However, its occasionally found in other countries, including the United States. In the spring of 2003, the first outbreak of mpox outside of Africa occurred in the U.S. A shipment of infected animals from Ghana was imported into Texas. The infected rodents spread the virus to pet prairie dogs, which then infected 47 people in the Midwest.
As international travel becomes more common, viruses that were once fairly confined to certain locations can more easily spread around the world. In the summer of 2021, a case of mpox was found in a U.S. resident who had traveled from Nigeria to the United States. Then, 2022 brought outbreaks to regions outside of Africa, including Europe, the Americas and Australia.
Anyone can get mpox. In Africa, most cases are among children under 15 years old. Outside of Africa, the disease appears to be more common in men who have sex with men, but there are numerous cases in people who dont fall into that category.
After exposure, it may be several days to a few weeks before you develop symptoms. Early signs of mpox include flu-like symptoms, including:
After a few days, a rash often develops. The rash starts as flat, red bumps, which can be painful. Those bumps turn into blisters, which fill with pus. Eventually, the blisters crust over and fall off the whole process can last two weeks to four weeks. You can also get sores in your mouth, vagina or anus.
Not everyone with mpox develops all the symptoms. In fact, in the current (2022) outbreak, many cases arent following the usual pattern of symptoms. This atypical presentation includes only a few lesions, no swollen lymph nodes, less fever and other signs of illness. You can have it and not know it. Even if you dont show many signs of infection, you can spread still spread it to others through prolonged close contact.
Mpox is spread when you come into contact with an animal or a person infected with the virus. Animal-to-person transmission occurs through broken skin, like from bites or scratches, or through direct contact with an infected animals blood, bodily fluids or pox lesions (sores).
Mpox can spread from person to person, but its less common. Person-to-person spread (transmission) occurs when you come in contact with the sores, scabs, respiratory droplets or oral fluids of a person who is infected, usually through close, intimate situations like cuddling, kissing or sex. Research is ongoing, but researchers arent sure if the virus is transmitted through semen or vaginal fluids.
You can also get mpox by coming into contact with recently contaminated materials like clothing, bedding and other linens used by a person who is infected or an infected animal.
Because mpox is rare, a healthcare provider may first suspect other rash illnesses, such as measles or chickenpox. But swollen lymph nodes usually distinguish mpox from other poxes.
To diagnose mpox, your healthcare provider takes a tissue sample from an open sore (lesion). Then, they send it to a lab for polymerase chain reaction (PCR) testing (genetic fingerprinting). You may also need to give a blood sample to check for the mpox virus or antibodies your immune system makes in defense of it.
Mpox is usually a self-limited disease with symptoms lasting from two weeks to four weeks. Most people with mpox get better on their own without treatment. Following diagnosis, your healthcare provider will monitor your condition and try to relieve your symptoms, prevent dehydration and give you antibiotics to treat secondary bacterial infections if they develop.
Theres not currently an approved antiviral treatment for mpox. Antiviral drugs may help, but they havent been studied as a treatment for mpox. Several investigational antivirals with activity against mpox are available, but only as part of a research study.
A smallpox vaccine provides protection against mpox, but its use is currently limited to clinical trials. Prevention depends on decreasing human contact with infected animals and limiting person-to-person spread. The best way to help prevent the spread of mpox virus is to:
Mpox normally takes about two weeks to four weeks to run its course. If youre exposed to mpox, your provider will monitor you until the rash resolves.
The less severe West African clade is causing the current world outbreak (2022). No one has died from this outbreak to date. But mpox can lead to other problems (complications) like pneumonia and infections in your brain (encephalitis) or eyes, which can be fatal.
If have mpox symptoms, there are over-the-counter medications that can help you feel better, including:
Call your healthcare provider if you:
Seek medical care if you develop the following symptoms:
Although they both cause skin rashes, different viruses cause mpox and chickenpox. Mpox is an orthopoxvirus, while chickenpox is a herpes virus. Both viruses can be spread through skin-to-skin or prolonged face-to-face contact, but chickenpox is very contagious and spreads more easily than mpox. People with mpox are more likely to have swollen lymph nodes than people with chickenpox.
The rashes act differently, too. While the chickenpox rash can appear in waves, mpox sores develop at the same time. Chickenpox symptoms including the rash tend to get better within two weeks, while it takes two weeks to four weeks for mpox to resolve.
Smallpox and mpox are both part of the orthopoxvirus family, so theyre caused by similar but distinct viruses. Thanks to effective vaccines, smallpox was eradicated (is no longer a circulating disease) by 1980. Smallpox was very contagious and spread more easily than mpox. Mpox symptoms are similar to smallpox, but milder.
A note from Cleveland Clinic
The last two years have been incredibly challenging the COVID-19 pandemic changed so much about the way we lived and worked. Now, just as were starting to ease back into regular life, were hearing media stories about mpox as an emerging threat. But mpox is a rare disease. Its spread through close contact, like kissing and sex though were still learning about how mpox spreads in humans. The best way to protect yourself is to avoid contact with people who are infected, wash your hands frequently and wear a face mask in crowded, indoor spaces. Early symptoms of mpox are flu-like and include fever, chills and body aches. After a few days, a rash will begin to develop. See a healthcare provider if you develop symptoms.
Continued here:
Mpox: Causes, Symptoms, Treatment & Prevention - Cleveland Clinic
--Preclinical studies show that ASC10-A, the active metabolite of double prodrug ASC10, has potent antiviral activities against both monkeypox and SARS-CoV-2 viruses
--Ascletis has received the Notice of Issuance from the United States Patent and Trademark Office (USPTO) for the patent application of ASC10 and its derivatives, and their uses to treat multiple virus infections
HANGZHOU and SHAOXING, China, Jan. 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application of ASC10 for monkeypox indication.
ASC10 is an oral double prodrug. After oral administration, both ASC10 and single prodrug molnupiravir are rapidly and completely converted in vivo into the same active metabolite ASC10-A, also known as -D-N4-hydroxycytidine (NHC) or EIDD-1931.
Preclinical studies show that ASC10-A has broad spectrum antiviral activities including potent activities against both monkeypox and SARS-CoV-2 viruses. Ascletis has received the Notice of Issuance from the United States Patent and Trademark Office (USPTO) for the patent application of ASC10 and its derivatives, and their uses to treat multiple virus infections including SARS-CoV-2, monkeypox virus and respiratory syncytial virus (RSV). Ascletis is the first Chinese biotech company which has been granted a patent by the USPTO for its in-house developed oral viral polymerase inhibitor and its derivatives.
Monkeypox virus is an orthopoxvirus that causes a disease with symptoms similar to smallpox[1]. As of January 25, 2023, over 85,106[2] confirmed cases have been reported globally and monkeypox virus has spread in 110 countries[2] according to data from World Health Organization (WHO).
Data from in vitro antiviral cellular assay with infectious monkeypox virus, a study sponsored by Ascletis and conducted at IIT Research Institute (IITRI) of Illinois Institute of Technology in Chicago, U.S., showed that ASC10-A has potent antiviral activity against monkeypox virus, suggesting that ASC10 has the potential to be an effective treatment of monkeypox virus infection. In August 2022, researchers from National Institute of Infectious Diseases, Tokyo, Japantested 132 drugs and the results showed that molnupiravir (active metabolite ASC10-A) and other two drugs have potent cellular antiviral activity in the infectious monkeypox virus assay[3]. The rest of 129 drugs such as remdesivir, favipiravir, sofosbuvir and ribavirin, etc. do not have antiviral activities against monkeypox virus[3].
Story continues
"I'm very glad that the IND application of ASC10 for monkeypox bas been approved by China NMPA, which further validates Ascletis' in-house R&D capabilities on viral diseases. Currently, there is no approved treatment for monkeypox in the world. We hope that ASC10 will make a contribution to the control of monkeypox globally." said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis.
[1] https://www.who.int/health-topics/monkeypox/#tab=tab_1
[2] https://worldhealthorg.shinyapps.io/mpx_global/
[3] Daisuke Akazawa, Hirofumi Ohashi, Takayuki Hishiki, et al. Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments. bioRxiv preprint. https://doi.org/10.1101/2022.08.02.502485
About Ascletis
Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and a proven track record, Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. Through excellent execution, Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. To date, Ascletis has three marketed products, i.e. ritonavir tablets, GANOVO and ASCLEVIR, and 22 drug candidates in its R&D pipeline. The most advanced drug candidates include ASC22 (HBV functional cure), ASC10 and ASC11(oral small molecules for COVID-19 treatment), ASC40 (recurrent glioblastoma), ASC42 (PBC, primary biliary cholangitis), and ASC40 (acne).
For more information, please visit http://www.ascletis.com.
SOURCE Ascletis Pharma Inc.
See the original post:
Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ...
Read the original post:
Epidemiologic and Clinical Features of Children and Adolescents ... Medscape
See the original post here:
Epidemiologic and Clinical Features of Children and Adolescents ... - Medscape
